What changed
$TMO — BUY 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $11.0B | EPS $5.44 vs $5.24 🟢 | Margin 21.8%
💡 Consensus expects modest ~5-6% organic growth and stable margins, but Thermo's PPI Business System and expanding product pipeline should drive stronger organic growth and margin accretion, leading to upward EPS estimate revisions and a re-rating closer to peers trading at higher forward multiples.
📉 Reward/risk: 2.5:1
🏢 Business Quality: 8/10 - Industry-leading life sciences tools franchise with sticky consumables, high ROIC, and consistent execution through cycles.
📊 Valuation: fair - at 26.6x TTM P/E, in line with historical median, but forward P/E of ~21x based on annualizing Q1 beat suggests undemanding valuation for a...
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/TMO0618